B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

door Shah, Nina, Chari, Ajai, Scott, Emma, Mezzi, Khalid, Usmani, Saad Z.
Gepubliceerd in Leukemia (2020)

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

door Chari, Ajai, Mezzi, Khalid, Zhu, Shao, Werther, Winifred, Felici, Diana, Lyon, Alexander R.
Gepubliceerd in BMC Cancer (2016)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

door Landgren, Ola, Sonneveld, Pieter, Jakubowiak, Andrzej, Mohty, Mohamad, Iskander, Karim S., Mezzi, Khalid, Siegel, David S.
Gepubliceerd in Leukemia (2019)

How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

door Cohen, Adam D., Raje, Noopur, Fowler, Jessica A., Mezzi, Khalid, Scott, Emma C, Dhodapkar, Madhav V.
Gepubliceerd in Clin Cancer Res (2019)

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

door Reece, Donna, Song, Kevin, LeBlanc, Richard, Mezzi, Khalid, Olujohungbe, Ade, White, Darrell, Zaman, Faraz, Belch, Andrew
Gepubliceerd in 2013

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting

door Rifkin, Robert M., Medhekar, Rohan, Amirian, E. Susan, Aguilar, Kathleen M., Wilson, Thomas, Boyd, Marley, Mezzi, Khalid, Panjabi, Sumeet
Gepubliceerd in Ther Adv Hematol (2019)

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

door Dimopoulos, Meletios, Siegel, David, White, Darrell J., Boccia, Ralph, Iskander, Karim S., Yang, Zhao, Kimball, Amy S., Mezzi, Khalid, Ludwig, Heinz, Niesvizky, Ruben
Gepubliceerd in Blood (2019)

Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress

door Wei, Andrew H., Roberts, Andrew W., Spencer, Andrew, Rosenberg, Aaron Seth, Siegel, David, Walter, Roland B., Caenepeel, Sean, Hughes, Paul, McIver, Zach, Mezzi, Khalid, Morrow, Phuong Khanh, Stein, Anthony
Gepubliceerd in Blood Rev (2020)

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

door Gormley, Nicole, Fashoyin-Aje, Lola, Locke, Trevan, Unger, Joseph M., Little, Richard F., Nooka, Ajay, Mezzi, Khalid, Popa-McKiver, Mihaela, Kobos, Rachel, Biru, Yelak, Williams, Tiffany H., Anderson, Kenneth C.
Gepubliceerd in Blood Cancer Discov (2021)

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

door Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Gepubliceerd in Cancer Med (2020)

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

door Facon, Thierry, Niesvizky, Ruben, Mateos, Maria-Victoria, Siegel, David, Rosenbaum, Cara, Bringhen, Sara, Weisel, Katja, Ho, P. Joy, Ludwig, Heinz, Kumar, Shaji, Wang, Kenneth, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra, Mezzi, Khalid, Goldrick, Amanda, Tekle, Christina, Dimopoulos, Meletios A.
Gepubliceerd in Blood Adv (2020)